C4 Therapeutics, Inc. Deferred Tax Assets, Unrealized Losses on Trading Securities
C4 Therapeutics, Inc. (CCCC) had Deferred Tax Assets, Unrealized Losses on Trading Securities of $0 as of 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities
us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities · last filed 2024-02-22
- 2023-12-31: Deferred Tax Assets, Unrealized Losses on Trading Securities $0.00.
- 2022-12-31: Deferred Tax Assets, Unrealized Losses on Trading Securities $1.09M.
- 2021-12-31: Deferred Tax Assets, Unrealized Losses on Trading Securities $195.00K.
| Period end | Deferred Tax Assets, Unrealized Losses on Trading Securities |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-22 |
| 2022-12-31 | $1.09M 10-K · filed 2024-02-22 |
| 2021-12-31 | $195.00K 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |